1. Home
  2. CLPS vs NRSN Comparison

CLPS vs NRSN Comparison

Compare CLPS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

N/A

Current Price

$1.00

Market Cap

26.8M

Sector

Technology

ML Signal

N/A

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.75

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
NRSN
Founded
2005
2017
Country
Hong Kong
Israel
Employees
N/A
16
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.8M
26.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CLPS
NRSN
Price
$1.00
$0.75
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
27.4K
108.5K
Earning Date
03-06-2026
03-31-2026
Dividend Yield
14.76%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$583.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.63
52 Week High
$1.88
$2.52

Technical Indicators

Market Signals
Indicator
CLPS
NRSN
Relative Strength Index (RSI) 61.17 40.83
Support Level $0.85 $0.74
Resistance Level $1.05 $0.75
Average True Range (ATR) 0.05 0.07
MACD 0.01 -0.01
Stochastic Oscillator 83.20 11.87

Price Performance

Historical Comparison
CLPS
NRSN

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: